CY1115575T1 - COMPOSITION FOR SUSPENSION - Google Patents

COMPOSITION FOR SUSPENSION

Info

Publication number
CY1115575T1
CY1115575T1 CY20141100769T CY141100769T CY1115575T1 CY 1115575 T1 CY1115575 T1 CY 1115575T1 CY 20141100769 T CY20141100769 T CY 20141100769T CY 141100769 T CY141100769 T CY 141100769T CY 1115575 T1 CY1115575 T1 CY 1115575T1
Authority
CY
Cyprus
Prior art keywords
month
twice
suspension
composition
once
Prior art date
Application number
CY20141100769T
Other languages
Greek (el)
Inventor
Anastasia Daifotis
Selwyn Aubrey Stoch
Basil Avery Ince
Cameron Black
Original Assignee
Merck Sharp & Dohme Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP06844077.5A external-priority patent/EP1855674B1/en
Application filed by Merck Sharp & Dohme Corp. filed Critical Merck Sharp & Dohme Corp.
Publication of CY1115575T1 publication Critical patent/CY1115575T1/en

Links

Abstract

Η παρούσα εφεύρεση αναφέρεται σε μέθοδο αναστολής της επαναρρόφησης οστού σε θηλαστικό που τη χρειάζεται με στοματική φαρμακευτική σύνθεση η οποία περιέχει αναστολέα της καθεψίνης Κ, ή φαρμακευτικώς αποδεκτό άλας του, ή μίγμα τους, σύμφωνα με συνεχές πρόγραμμα το οποίο έχει διάστημα δοσολογίας μια φορά εβδομαδιαίως, δύο φορές εβδομαδιαίως, δύο φορές μηνιαίως ή μια φορά μηνιαίως.The present invention relates to a method of inhibiting mammalian bone resorption by an oral pharmaceutical composition containing an inhibitor of cathepsin K, or a pharmaceutically acceptable salt thereof, or a mixture thereof, according to a continuous schedule having a once weekly dosage interval, twice a week, twice a month or once a month.

CY20141100769T 2005-03-02 2014-09-23 COMPOSITION FOR SUSPENSION CY1115575T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65798205A 2005-03-02 2005-03-02
EP06844077.5A EP1855674B1 (en) 2005-03-02 2006-02-24 Composition for inhibition of cathepsin k

Publications (1)

Publication Number Publication Date
CY1115575T1 true CY1115575T1 (en) 2017-01-04

Family

ID=58461564

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100769T CY1115575T1 (en) 2005-03-02 2014-09-23 COMPOSITION FOR SUSPENSION

Country Status (1)

Country Link
CY (1) CY1115575T1 (en)

Similar Documents

Publication Publication Date Title
CY1106457T1 (en) PHARMACEUTICAL COMPOSITION FOR USE IN HORMONE REPLACEMENT THERAPY
CY1118196T1 (en) NEW CRYSTAL FORM VI OF AGOMELATIN, METHOD OF PRODUCE THIS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING IT
CY1118156T1 (en) AMIDE REVERSE COMPOUNDS AS PROTEIN DETERMINATION INHIBITORS AND METHODS OF USING THESE
CY1117753T1 (en) Crystalline form of Perindopril Arginine Salt, Method of Preparation and Pharmaceutical Compositions Containing It
CY1118637T1 (en) NEW CRYSTAL FORM III OF AGOMELATIN, METHOD OF PREPARING THIS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING IT
EA200600323A1 (en) γd CRYSTALLINE FORM OF Ivabradine Hydrochloride, Method for its Production and Pharmaceutical Compositions That It Contains
CY1118231T1 (en) COMPOSITION OF Liposome
TW200833370A (en) Pharmaceutical composition containing low substituted hydroxypropylcellulose
NO20055590L (en) Kinase Inhibiting Phosphonate Analogs
IL172513A0 (en) Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation
EA200870217A1 (en) 4-Aryl-2-aminopyrimidines or 4-aryl-2-aminoalkylpyrimidines as modulators JAK-2 and containing their pharmaceutical compositions
EA200601273A1 (en) NEW CRYSTAL FORM V AGOMELATIN, THE METHOD OF ITS OBTAINING AND PHARMACEUTICAL COMPOSITIONS THAT HERE CONTAINS
SE0101675D0 (en) Novel composition
EA200601271A1 (en) NEW CRYSTAL FORM IV OF AGOMELATIN, THE METHOD OF ITS OBTAINING AND PHARMACEUTICAL COMPOSITIONS THAT HERE CONTAINS
DE602004008959D1 (en) BENZOÄBÜÄ1,4ÜDIOXEPINDERIVATE
EA200971115A1 (en) NEW HIV REVERSE TRANSCRIPTASE INHIBITORS
SI1663989T1 (en) CRYSTALLINE FORM OF BIS (E)-7- 4-(4-FLUOROPHENYL)-6-IS OPROPYL-2- METHYL(METHYLSULFONYL)AMINO PYRIMIDIN-5-YL&r sqb;(3R,5S)-3,5-DIHYDROXYHEPT-6 -ENOICACID CALCIUM SALT
CY1113594T1 (en) FUMARIC SALT (ALPHA S, BETA R) -6-BROOM-ALPHA- [2- (BIMETHYLAMINE) ETHYL] -2-Methoxy-alpha-1-naphthalinyl-beta-phenyl-3-phenyl
CY1112451T1 (en) METHOD FOR REDUCING GASTROENTRIC TOXICITY BY TEGAPURIS ADMINISTRATION
EA201270410A1 (en) INDENONA DERIVATIVE AND CONTAINING ITS PHARMACEUTICAL COMPOSITION
MX2008010747A (en) β-crystalline form of perindopril arginine salt, method for making same, and pharmaceutical compositions containing same.
EA201190293A1 (en) TRIPOLIDA SPIRITS
EA200800393A1 (en) NEW COMPOUNDS-ANALOGUES OF CAMPTOTECINE, METHOD FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
MX2021014773A (en) Crystalline salt forms of a kinase inhibitor.
EA200600760A1 (en) NEW COMPOUNDS PHENILPYRIDILPIPERAZINE, METHOD OF THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM